Juan Luis Steegmann
YOU?
Author Swipe
View article: Supplemental video S2 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S2 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Recovery of HUVEC monolayer after washing out dasatinib.
View article: Supplemental video S2 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S2 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Recovery of HUVEC monolayer after washing out dasatinib.
View article: Supplemental video S3 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S3 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Wound healing in control conditions.
View article: Figure S5 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Figure S5 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Evans Blue endothelial permeability assay shows leakage in the intestine of mice treated with dasatinib.
View article: Supplemental video S4 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S4 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Wound healing in the presence of 100 nM dasatinib.
View article: Figure S5 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Figure S5 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Evans Blue endothelial permeability assay shows leakage in the intestine of mice treated with dasatinib.
View article: Supplemental video S4 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S4 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Wound healing in the presence of 100 nM dasatinib.
View article: Data from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Data from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Purpose: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, patients taking dasatinib often display severe adverse ef…
View article: Supplemental video S1 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S1 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
100nM dasatinib was added on a monolayer of HUVECs.
View article: Supplemental video S1 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S1 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
100nM dasatinib was added on a monolayer of HUVECs.
View article: Supplemental video S3 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Supplemental video S3 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Wound healing in control conditions.
View article: Data from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Data from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner Open
Purpose: Dasatinib is a short-acting dual ABL/SRC family tyrosine kinase inhibitor (TKI), which is frequently used to treat chronic myeloid leukemia. Although very effective, patients taking dasatinib often display severe adverse ef…
View article: Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia Open
View article: Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission Open
BCR-ABL is an aberrant tyrosine kinase responsible for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs) induce a potent antileukemic response mostly based on the inhibition of BCR-ABL, but they also increase the activity o…
View article: Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection Open
View article: Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia Open
View article: Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study Open
View article: Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure Open
Asciminib was active in heavily pretreated patients with CML who had resistance to or unacceptable side effects from TKIs, including patients in whom ponatinib had failed and those with a T315I mutation. (Funded by Novartis Pharmaceuticals…
View article: CD4 T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors
CD4 T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors Open
View article: Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients Open
Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, …
View article: PB2230 SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB‐OZOGAMICIN
PB2230 SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM, EVOLVING TO SIMULTANEOUS CD33 POSITIVE MAST CELL LEUKEMIA AND ACUTE MYELOID LEUKEMIA, TREATED WITH GEMTUZUMAB‐OZOGAMICIN Open
Background: Mast cell leukemia (MCL) is an extremely rare subtype of systemic mastocytosis (SM), with only 50 cases described so far. It confers an extremely bad prognosis, with an overall survival of few months. Aims: To describe an extre…
View article: PF419 ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS)
PF419 ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS) Open
Background: Given the good survival outcome of CML patients treated with TKI, and the prognostic value of age at diagnosis, it is needed to dissect more precisely the relative weight of this variable, considering other prognostic variable …
View article: PB1960 CHRONIC MYELOID LEUKEMIA DEVELOPING AFTER SYSTEMIC MASTOCYTOSIS: FAST AND COMPLETE MOLECULAR RESPONSE INDUCED BY IMATINIB.
PB1960 CHRONIC MYELOID LEUKEMIA DEVELOPING AFTER SYSTEMIC MASTOCYTOSIS: FAST AND COMPLETE MOLECULAR RESPONSE INDUCED BY IMATINIB. Open
Background: We present here the case of a 52 year old male patient who was diagnosed of D816 V + indolent systemic mastocytosis in 2006. The patient received only symptomatic treatment with fexofenadine, sodium cromoglycate, and ranitidine…
View article: PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL
PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL Open
Background: Bosutinib (BOS) is approved in patients (pts) with Philadelphia chromosome‐positive (Ph+) chronic myeloid leukemia (CML) who are newly diagnosed (400 mg once daily [QD]) or resistant or intolerant to prior treatment (tx; 500 mg…
View article: Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients Open
View article: Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCKdependent manner.
Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCKdependent manner. Open
View article: Effect of tyrosine kinase inhibitors on the cytotoxic activity against HIV-1 infection
Effect of tyrosine kinase inhibitors on the cytotoxic activity against HIV-1 infection Open
View article: Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase Open
View article: PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase Open
Patched homolog 1 gene (PTCH1) expression and the ratio of PTCH1 to Smoothened (SMO) expression have been proposed as prognostic markers of the response of chronic myeloid leukemia (CML) patients to imatinib. We compared these measurements…
View article: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase Open
Purpose This study was aimed to analyze the association of very early molecular response to nilotinib with the achievement of deep molecular response (MR4) at 18 months. We hypothesized that the BCR-ABL1 levels during the first 3 months of…